Show simple item record

dc.contributor.authorCastelnuovo, Barbara
dc.contributor.authorNanyonjo, Agnes
dc.contributor.authorKamya, Moses
dc.contributor.authorOcama, Ponsiano
dc.date.accessioned2012-01-25T12:01:03Z
dc.date.available2012-01-25T12:01:03Z
dc.date.issued2008-06
dc.identifier.citationCastelnuovo, B.,Nanyonjo, A.,Kamya, R.,Ocama, P. (2008). Is it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?, 8(2)en_US
dc.identifier.issn1680-6905
dc.identifier.urihttp://hdl.handle.net/10570/351
dc.description.abstractIntroduction: In resource limited settings patients on antiretroviral treatment who develop stavudine induced hyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. Case report: We describe here a case of a 60 year old female that experienced a relapse of symptomatic hyperlactatemia after being switched from stavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. Discussion: This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse. Therefore we recommend close follow up for patients that are switched from stavudine to zidovudine and, in case lactate measurement is not possible, free programs should provide safer drugs such as abacavir and tenofovir for patients that develop hyperlactatemia.en_US
dc.language.isoenen_US
dc.publisherAfrican Health Sciencesen_US
dc.subjectResource limited settingsen_US
dc.subjectAntiretroviral treatmenten_US
dc.subjectHIV/AIDSen_US
dc.subjectUgandaen_US
dc.subjectSymptomatic hyperlactatemiaen_US
dc.subjectCD4+ counten_US
dc.titleIs it safe to switch from stavudine to zidovudine after developing symptomatic hyperlactatemia?en_US
dc.typeJournal article, peer revieweden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record